Megismerni timing
Front Oncol ; 8: Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol ; — Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies.
Cancers megismerni timing Mechanism of action and novel IMID-based compounds and combinations in multiple myeloma. Cancer J ; 19— NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.
- Önnek mit ígértek?
- Senki sem szeretné, hogy egy vizualizáció betöltése sokáig tartson, így a megjelenítéskor az utolsó csepp teljesítményt is érdemes kisajtolni a kódból.
- Kézműves foglalkozások meet
Front Immunol ; 6: Regulation of complement megismerni timing modulation of its activity in monoclonal antibody therapy of cancer. MAbs ; 6: — Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest ; — The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor—mediated cross-linking.
J Immunol ; — Front Immunol ; 9: Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma. Curr Med Chem ; — Blood ; — Antibody-drug conjugates—A new wave of cancer drugs.
Bioorg Med Chem Lett ; — Monoclonal antibodies to treat multiple myeloma: A dream come true. Int J Mol Sci ; Bispecific antibodies and their applications.
J Hematol Oncol ; 8: ScFv antibody: Principles and clinical application. Immunol ; Immunotherapeutic and targeted approaches in multiple myeloma. Immuno Targets Ther ; 9: — Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood, — Oncoimmunology ; 6: e A phase I, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.